Skip to content
Bipartisan legislation to support research into rare diseases received backing from witnesses and lawmakers during a Feb. 29 hearing of the House Energy and […]
Lawmakers back bipartisan legislation supporting rare disease research Read More »
Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also
Biotech investment is scarce, but still available, experts tell CEOs Read More »
Mergers and acquisitions (M&A) are important elements of the biotech industry, especially for early-stage fundraising and bringing new drugs and treatments to the market.
What biotech companies should know about M&A in down markets Read More »
The metabolic field is the hottest biotech therapeutic area of the year (and likely to continue beyond). In the context of a difficult couple
The future of next-generation obesity drugs Read More »
Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ORPHAN Cures Act and
CEOs ask Congress to pass ORPHAN Cures Act Read More »
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to
Drug developers and investors need to join AI revolution, panel says Read More »
The biotech industry must constantly navigate the ins and outs of Beltway politics. During an election year, the need to anticipate and plan for
What policy biotech should be watching this election year Read More »
Rare Disease Week 2024, taking place February 25–28, is an important annual reminder of the need to find cures and improve therapies for patients.
Rare Disease Week 2024: standing up for 1 in 10 Americans Read More »
The Biotechnology Innovations Organization (BIO) report, The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases, on January 25, 2024, found that
CEOs explore challenges and opportunities in vaccine pipeline Read More »
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and
CEOs say market must keep up with the science of gene therapies Read More »
